Author:
Lentz Robert J.,Frederick-Dyer Katherine,Planz Virginia B.,Koyama Tatsuki,Aboudara Matthew C.,Swanner Briana,Roller Lance,Low See-Wei,Salmon Cristina,Avasarala Sameer K.,Hoopman Todd C.,Wahidi Momen M.,Mahmood Kamran,Cheng George Z.,Katsis James M.,Kurman Jonathan S.,D’Haese Pierre-François,Johnson Joyce,Grogan Eric L.,Walston Charla,Yarmus Lonny,Silvestri Gerard A.,Rickman Otis B.,Rahman Najib M.,Maldonado Fabien
Abstract
ABSTRACTBackgroundLung nodule incidence is increasing. Many nodules require biopsy to discriminate between benign and malignant etiologies. The gold-standard for minimally invasive biopsy, computed tomography-guided transthoracic needle biopsy (CT-TTNB), has never been directly compared to navigational bronchoscopy, a modality which has recently seen rapid technological innovation and is associated with improving diagnostic yield and lower complication rate. Current estimates of the diagnostic utility of both modalities are based largely on non-comparative data with significant risk for selection, referral, and publication biases.MethodsThe VERITAS trial (naVigationEndoscopy toReach Indeterminate lung nodules versusTransthoracic needleAspiration, a randomized controlledStudy) is a multicenter, 1:1 randomized, parallel-group trial designed to ascertain whether electromagnetic navigational bronchoscopy with integrated digital tomosynthesis is noninferior to CT-TTNB for the diagnosis of peripheral lung nodules 10-30 mm in diameter with pre-test probability of malignancy of at least 10%. The primary endpoint is diagnostic accuracy through 12 months follow-up. Secondary endpoints include diagnostic yield, complication rate, procedure duration, need for additional invasive diagnostic procedures, and radiation exposure.DiscussionThe results of this rigorously designed trial will provide high-quality data regarding the management of lung nodules, a common clinical entity which often represents the earliest and most treatable stage of lung cancer. Several design challenges are described. Notably, all nodules are centrally reviewed by an independent interventional pulmonology and radiology adjudication panel relying on pre-specified exclusions to ensure enrolled nodules are amenable to sampling by both modalities while simultaneously protecting against selection bias favoring either modality. Conservative diagnostic yield and accuracy definitions with pre-specified criteria for what non-malignant findings may be considered diagnostic were chosen to avoid inflation of estimates of diagnostic utility.Trial registrationClinicalTrials.govNCT04250194
Publisher
Cold Spring Harbor Laboratory